{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:23:46Z","timestamp":1790033026320,"version":"4.0.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81660109"],"award-info":[{"award-number":["81660109"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005198","name":"Chinese Foundation for Hepatitis Prevention and Control","doi-asserted-by":"publisher","award":["MX202418"],"award-info":[{"award-number":["MX202418"]}],"id":[{"id":"10.13039\/501100005198","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.aohep.2025.101925","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T15:57:37Z","timestamp":1749657457000},"page":"101925","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Improvement in renal function after switching from entecavir to tenofovir alafenamide in chronic hepatitis B patients with low estimated glomerular filtration rates"],"prefix":"10.1016","volume":"30","author":[{"given":"Liang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shipeng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajpat Rai","family":"Malhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanfei","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10381","key":"10.1016\/j.aohep.2025.101925_bib0001","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","article-title":"Hepatitis B","volume":"401","author":"Jeng","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.aohep.2025.101925_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22010213","article-title":"Hepatitis B virus cure: targets and future therapies","volume":"22","author":"Lee","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.aohep.2025.101925_bib0003","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00046-19","article-title":"Hepatitis B virus: advances in prevention, diagnosis, and therapy","volume":"33","author":"Nguyen","year":"2020","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"10.1016\/j.aohep.2025.101925_bib0004","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.jhep.2022.07.003","article-title":"Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: a systematic review, meta-analysis, and expert opinion","volume":"77","author":"Papatheodoridis","year":"2022","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.aohep.2025.101925_bib0005","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jhep.2021.05.013","article-title":"Covalently closed circular DNA: the ultimate therapeutic target for curing HBV infections","volume":"75","author":"Martinez","year":"2021","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.aohep.2025.101925_bib0006","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/jmv.25925","article-title":"Serum HBV RNA composition dynamics as a marker for intrahepatic HBV cccDNA turnover","volume":"92","author":"Hong","year":"2020","journal-title":"J Med Virol"},{"issue":"2","key":"10.1016\/j.aohep.2025.101925_bib0007","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"Clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.aohep.2025.101925_bib0008","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3350\/cmh.2022.0084","article-title":"KASL clinical practice guidelines for management of chronic hepatitis B","volume":"28","year":"2022","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"10.1016\/j.aohep.2025.101925_bib0009","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s12072-021-10285-5","article-title":"Asian pacific association for the study of liver (APASL) guidelines: hepatitis B virus in pregnancy","volume":"16","author":"Kumar","year":"2022","journal-title":"Hepatol Int"},{"issue":"10","key":"10.1016\/j.aohep.2025.101925_bib0010","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1111\/apt.16097","article-title":"East Asia expert opinion on treatment initiation for chronic hepatitis B","volume":"52","author":"Kao","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.aohep.2025.101925_bib0011","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3947\/ic.2023.0001","article-title":"Incidence and risk factors of tenofovir disoproxil fumarate induced nephrotoxicity and renal function recovery, a hospital case-control study","volume":"55","author":"Srisopa","year":"2023","journal-title":"Infect Chemother"},{"issue":"1","key":"10.1016\/j.aohep.2025.101925_bib0012","doi-asserted-by":"crossref","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"issue":"1","key":"10.1016\/j.aohep.2025.101925_bib0013","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.aohep.2025.101925_bib0014","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/liv.15208","article-title":"Higher risk of kidney function decline with entecavir than tenofovir alafenamide in patients with chronic hepatitis B","volume":"42","author":"Jung","year":"2022","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.aohep.2025.101925_bib0015","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.aohep.2025.101925_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101119","article-title":"Improved bone and renal safety in younger tenofovir disoproxil fumarate experienced chronic hepatitis B patients after switching to tenofovir alafenamide or entecavir","volume":"28","author":"Da Wang","year":"2023","journal-title":"Ann Hepatol"},{"issue":"6","key":"10.1016\/j.aohep.2025.101925_bib0017","first-page":"1425","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)","volume":"11","author":"You","year":"2023","journal-title":"J Clin Transl Hepatol"},{"issue":"24","key":"10.1016\/j.aohep.2025.101925_bib0018","doi-asserted-by":"crossref","first-page":"6306","DOI":"10.12998\/wjcc.v8.i24.6306","article-title":"Early renal injury indicators can help evaluate renal injury in patients with chronic hepatitis B with long-term nucleos(t)ide therapy","volume":"8","author":"Ji","year":"2020","journal-title":"World J Clin Cases"},{"issue":"4","key":"10.1016\/j.aohep.2025.101925_bib0019","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.aohep.2025.101925_bib0020","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/jmv.25515","article-title":"Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B","volume":"91","author":"Hagiwara","year":"2019","journal-title":"J Med Virol"},{"issue":"4","key":"10.1016\/j.aohep.2025.101925_bib0021","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/apt.17819","article-title":"Longitudinal changes in renal function in patients with chronic hepatitis B on antiviral treatment","volume":"59","author":"Hong","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.aohep.2025.101925_bib0022","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1186\/s12879-021-06237-x","article-title":"Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B","volume":"21","author":"Li","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"3","key":"10.1016\/j.aohep.2025.101925_bib0023","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/jvh.13222","article-title":"An observational study on long-term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate","volume":"27","author":"Lim","year":"2020","journal-title":"J Viral Hepatitis"},{"issue":"7","key":"10.1016\/j.aohep.2025.101925_bib0024","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/liv.14482","article-title":"Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B","volume":"40","author":"Ogawa","year":"2020","journal-title":"Liver Int"},{"issue":"8","key":"10.1016\/j.aohep.2025.101925_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2012.04.008","article-title":"Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B","volume":"10","author":"Gish","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.aohep.2025.101925_bib0026","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/apt.17785","article-title":"Increased spine bone density in patients with chronic hepatitis B switched to tenofovir alafenamide: a prospective, multinational study","volume":"59","author":"Ogawa","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"34","key":"10.1016\/j.aohep.2025.101925_bib0027","doi-asserted-by":"crossref","first-page":"8139","DOI":"10.12998\/wjcc.v11.i34.8139","article-title":"Efficacy and safety of tenofovir alafenamide in patients with chronic hepatitis B exhibiting suboptimal response to entecavir","volume":"11","author":"Yuan","year":"2023","journal-title":"World J Clin Cases"},{"issue":"11","key":"10.1016\/j.aohep.2025.101925_bib0028","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.14309\/ajg.0000000000002234","article-title":"Personalized antiviral drug selection in patients with chronic hepatitis B using a machine learning model: a multinational study","volume":"118","author":"Hur","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.aohep.2025.101925_bib0029","doi-asserted-by":"crossref","first-page":"712","DOI":"10.5009\/gnl.2013.7.6.712","article-title":"Continuous long-term entecavir therapy in na\u00efve chronic hepatitis B patients showing partial virologic response","volume":"7","author":"Kwon","year":"2013","journal-title":"Gut Liver"},{"issue":"3","key":"10.1016\/j.aohep.2025.101925_bib0030","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/jmv.25608","article-title":"Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir","volume":"92","author":"Wang","year":"2020","journal-title":"J Med Virol"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268125001504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268125001504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T09:36:17Z","timestamp":1764668177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268125001504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1665268125001504"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2025.101925","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improvement in renal function after switching from entecavir to tenofovir alafenamide in chronic hepatitis B patients with low estimated glomerular filtration rates","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2025.101925","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"101925"}}